Discovery of WRN inhibitor HRO761 with synthetic lethality in MSI cancers
Nature – HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation.
Nature – HRO761 is a potent, selective, allosteric WRN inhibitor that binds at the interface of the D1 and D2 helicase domains, locking WRN in an inactive conformation.
In a scorching talk, marketing professor and podcaster Scott Galloway dissects the data showing that, by many measures, young people in the US are worse…
Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer
The NHS needs more doctors so why have some medical students been left in limbo waiting for a job?
1 MT3 Clinical Education and Consulting, Coon Rapids, MN, United States 2 Faculty of Rehabilitation Medicine, University of Alberta, Edmonton, AB, Canada 3 Client Experience…
PURPOSE Chemotherapy is established as primary treatment in patients with stage IV colorectal cancer and unresectable metastases. Data from nonrandomized clinical trials have fueled persistent…
Abstract. Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissue-agnostic targets have been characterized and explored, which ultimately led…
As more NHS trusts in England report budget deficits health leaders warn that waiting lists will rise
archived 5 May 2024 07:01:05 UTC
They earn the country hundreds of billions but are being undermined by constant criticism and curbs on overseas students
Walsh and colleagues call for prudence in their editorial on lecanemab for Alzheimer’s disease. This call should be extended to dementia and Alzheimer’s disease research…